Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kiniksa Pharmaceuticals Ltd
KNSA | US
46.74
USD0.58
1.26%
KNSA | US
About Kiniksa Pharmaceuticals Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
46.74
Open
46.01
High
46.86
Low
44.45
Kiniksa Pharmaceuticals Ltd. a biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST an interleukin-1alpha and interleukin-1beta for the treatment of recurrent pericarditis which is an inflammatory cardiovascular disease; Mavrilimumab a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab a monoclonal antibody that completed Phase 2b clinical trial for the treatment of prurigo nodularis a chronic inflammatory skin condition; and KPL-404 a monoclonal antibody inhibitor of the CD40- CD154 interaction a T-cell co-stimulatory signal critical for B-cell maturation immunoglobulin class switching and type 1 immune response. Kiniksa Pharmaceuticals Ltd. was incorporated in 2015 and is based in Hamilton Bermuda.
View LessKNSA | US
Risk
43.7
Sharpe
2.60
Luna's Score
72/100
Recommendation
Buy
Luna says (KNSA | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
54.6%1 month
43.7%3 months
39.0%6 months
35.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.30
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-44.93
Ent. to rev.
4.91
PEG
-
Other Fundamentals
EBITDA
-25.47M
MarketCap
3.33B
MarketCap(USD)
3.33B
Div. yield
-
Op. margin
-0.11
Erngs. growth
550.00
Rev. growth
52.00
Ret. on equity
-2.42
Short ratio
8.51
Short perc.
13.04
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
8.00
Range1M
8.00
Range3M
12.10
Volumes: Market Activity
Rel. volume
0.73
Price X volume
22.44M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -44.93 | 0.53 | Cheaper |
| Ent. to Revenue | 4.91 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.30 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 38.97 | 72.80 | Lower Risk |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 3.33B | 3.66B | Par |
